2025
WS16.05Impact of elexacaftor/tezacaftor/ivacaftor on glucose tolerance in adolescents with cystic fibrosis. Data from the MODUL-CF study
Bonnel A, Galderisi A, Weiss L, Sermet-Gaudelus I, Besancon A, Letierce A, Sahki D, Group M. WS16.05Impact of elexacaftor/tezacaftor/ivacaftor on glucose tolerance in adolescents with cystic fibrosis. Data from the MODUL-CF study. Journal Of Cystic Fibrosis 2025, 24: s33. DOI: 10.1016/j.jcf.2025.03.586.Peer-Reviewed Original ResearchOral glucose tolerance testAbnormal glucose toleranceNormal glucose toleranceCF-related diabetesBaseline oral glucose tolerance testAbnormal glucose tolerance groupCystic fibrosisGlucose toleranceNormal glucose tolerance groupEffective CFTR modulatorsOGTT glucoseBMI z-scoreYear of treatmentImpaired fasting glucoseImpaired glucose toleranceGlucose tolerance testForced expiratory volumeCFTR modulatorsPulmonary infectionDecrease recurrenceBaseline characteristicsRelated diabetesFasting GlucoseTolerance testInsulin treatmentEffect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis
Galderisi A, Weiss L, Besançon A, Stremler N, Reix P, Wizla N, Lustre A, Rames C, Tatopoulos A, Perisson C, Dalphin M, Troussier F, Houdouin V, Bessaci K, Cosson L, Gabsi A, Corvol H, Deneuville E, Storni V, Ramel S, Bui S, Heraud M, Remus N, Huet F, Scalbert M, Mely L, Gachelin E, Giannantonio M, Letierce A, Sahki D, Marguet C, Bonnel A, Sermet-Gaudelus I. Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis. The Journal Of Clinical Endocrinology & Metabolism 2025, dgaf099. PMID: 39977216, DOI: 10.1210/clinem/dgaf099.Peer-Reviewed Original ResearchOral glucose tolerance testBaseline oral glucose tolerance testAbnormal glucose toleranceNormal glucose toleranceAbnormal glucose tolerance groupCystic fibrosisGlucose toleranceNormal glucose tolerance groupEffective CFTR modulatorsCF-related diabetesInsulin secretionImpaired fasting glucoseGlucose tolerance testImpaired glucose toleranceForced expiratory volumeBMIz-scoreCFTR modulatorsBaseline characteristicsRelated diabetesFasting GlucoseTolerance testTherapeutic strategiesInsulin treatmentExpiratory volumeGlucose levelsImpacts of Obesity-Induced Insulin and Leptin Dysregulation on Ovarian Function and Fertility
Rodriguez Y, Yang-Hartwich Y, Perry R. Impacts of Obesity-Induced Insulin and Leptin Dysregulation on Ovarian Function and Fertility. Physiology 2025, 40: 1996. DOI: 10.1152/physiol.2025.40.s1.1996.Peer-Reviewed Original ResearchOvarian functionOvarian tissueObesogenic contextRestore ovarian functionOvarian cell functionsResponse to hormonal changesCell viabilityImpact reproductive healthChow-fed controlsHuman granulosa-like tumorGlucose uptakeImproving fertility outcomesPotential therapeutic interventionsLeptin dysregulationCell proliferation assayHFD-fed miceLeptin treatmentGranulosa cellsLeptin resistanceOvarian environmentOvarian cellsReduced cell viabilityHormonal dysregulationLeptin signalingInsulin treatment
2023
Triglyceride Clearance in Hypertriglyceridemic Pancreatitis: Time Course and Its Implications for Management
Majumdar S. Triglyceride Clearance in Hypertriglyceridemic Pancreatitis: Time Course and Its Implications for Management. Endocrine Practice 2023, 29: 971-979. PMID: 37714331, DOI: 10.1016/j.eprac.2023.09.002.Peer-Reviewed Original ResearchInitial TG levelsTG levelsInsulin therapyMedical record reviewDiagnosis of pancreatitisTime courseHypertriglyceridemic pancreatitisIntravenous insulinRecord reviewTime-course evaluationTriglyceride clearanceInsulin treatmentNutritional intakeSeparate patientsTG loweringDlPatientsLonger durationPancreatitisShort durationHTGTherapyCauseClearanceDaysEarly treatment of neonatal diabetes with oral glibenclamide in an extremely preterm infant
Galderisi A, Kermorvant‐Duchemin E, Daruich A, Bonnard A, Lapillonne A, Aubelle M, Perrella B, Vial Y, Cave H, Berdugo M, Jarreau P, Polak M, Beltrand J. Early treatment of neonatal diabetes with oral glibenclamide in an extremely preterm infant. 2023, 64: 161-166. PMID: 36873092, PMCID: PMC9981413, DOI: 10.1002/jmd2.12358.Peer-Reviewed Original ResearchEarly treatmentNeonatal diabetesPreterm babiesPreterm infantsGlucose profilesComplete retinal vascularizationLow glucose intakeBlood glucose testMonth of birthOral glibenclamideGlycemic controlMonth 6Gestational ageNasogastric tubeRetinal vascularizationMaternal milkGlucose intakeInsulin treatmentKCNJ11 genesGlucose testHyperglycemic episodesSpecific treatmentProgressive regressionDiabetesHomozygous variant
2022
Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study
Wolf RM, Cheng P, Gal RL, Beaulieu LC, Kollman C, Isganaitis E, Magge S, Mastrandrea LD, Klingensmith GJ, Tamborlane W, Van Name M, Consortium P. Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study. Pediatric Diabetes 2022, 23: 439-446. PMID: 35138021, DOI: 10.1111/pedi.13325.Peer-Reviewed Original ResearchConceptsIntensive lifestyle interventionTreatment failureType 2 diabetesDiabetes medicationsLifestyle interventionGlycemic controlDiscontinuation of insulinExperienced treatment failureInitial insulin treatmentYouth-onset T2DHigh rateMetformin monotherapyPrimary outcomeMedian timeRisk factorsInsulin treatmentMetforminProgressive natureConsortium studyLogistic regressionInsulinT2DIntensive lifestyleMedicationsDiabetes
2020
Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition
Akoumianakis I, Badi I, Douglas G, Chuaiphichai S, Herdman L, Akawi N, Margaritis M, Antonopoulos AS, Oikonomou EK, Psarros C, Galiatsatos N, Tousoulis D, Kardos A, Sayeed R, Krasopoulos G, Petrou M, Schwahn U, Wohlfart P, Tennagels N, Channon KM, Antoniades C. Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition. Science Translational Medicine 2020, 12 PMID: 32350133, PMCID: PMC7212010, DOI: 10.1126/scitranslmed.aav8824.Peer-Reviewed Original ResearchConceptsDipeptidyl peptidase-4 inhibitorsCoronary artery bypass surgeryAggressive insulin treatmentInsulin treatmentCoronary atherosclerosisEndothelial functionAbnormal responseHigh-fat diet-fed ApoEOral dipeptidyl peptidase-4 inhibitorLong-term combination therapyHuman internal mammary arteryDipeptidyl peptidase-4 inhibitionHigher cardiac mortalityPeptidase-4 inhibitionVascular insulin responsesVascular redox stateArtery bypass surgeryInternal mammary arteryInsulin resistance statusNitric oxide bioavailabilityPeptidase-4 inhibitorsPlasma DPP4 activityVascular oxidative stressRecent clinical trialsInsulin-sensitizing effectsChildren and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control
Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV, Consortium F. Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control. Diabetic Medicine 2020, 37: 863-867. PMID: 31943374, DOI: 10.1111/dme.14233.Peer-Reviewed Original ResearchConceptsType 2 diabetesType 1 diabetesPediatric Diabetes ConsortiumTarget HbAType 1Median C-peptide levelsResidual endogenous insulin secretionType 2 diabetes mellitusC-peptide levelsEndogenous insulin secretionOverweight/obeseYears of agePoor diabetes outcomesSubset of participantsCharacteristics of childrenDiabetic ketoacidosisGlycaemic controlClinical characteristicsDiabetes mellitusDiabetes outcomesRisk factorsFamilies of childrenInsulin secretionInsulin treatmentDiabetes diagnosis
2019
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
Danne T, Pettus J, Giaccari A, Cariou B, Rodbard H, Weinzimer S, Bonnemaire M, Sawhney S, Stewart J, Wang S, de Cassia Castro R, Garg S. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2019, 21: 471-477. PMID: 31335194, PMCID: PMC6708262, DOI: 10.1089/dia.2019.0157.Peer-Reviewed Original ResearchConceptsSotagliflozin 200Insulin therapyHypoglycemia eventsRate of hypoglycemiaType 1 diabetesLevel 2 hypoglycemiaLower ratesImportant hypoglycemiaHypoglycemia ratesWeek 52Adult patientsGlycemic controlHypoglycemic eventsHypoglycemic rateClinical trialsInsulin treatmentPlaceboSotagliflozinHypoglycemiaType 1Phase 3PatientsTherapyWeeksAdultsA Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes.
Galderisi A, Sherr JL. A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes. Pediatric Annals 2019, 48: e311-e318. PMID: 31426099, DOI: 10.3928/19382359-20190725-03.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsContinuous glucose monitoringType 1 diabetesGlycemic controlContinuous subcutaneous insulin infusion pumpClosed-loop insulin deliveryIntensive insulin treatmentMultiple daily injectionsChronic medical conditionsLoop insulin deliveryPediatric clinical practiceInsulin infusion pumpDaily injectionsBlood glucoseInsulin treatmentMedical conditionsDiabetes treatmentClinical practiceNew treatmentsGlucose monitoringInfusion pumpInsulin deliveryT1DDiabetesTreatmentSuspension device
2017
Evaluating the role of race and medication in protection of uterine fibroids by type 2 diabetes exposure
Velez Edwards D, Hartmann K, Wellons M, Shah A, Xu H, Edwards T. Evaluating the role of race and medication in protection of uterine fibroids by type 2 diabetes exposure. BMC Women's Health 2017, 17: 28. PMID: 28399866, PMCID: PMC5387248, DOI: 10.1186/s12905-017-0386-y.Peer-Reviewed Original ResearchConceptsT2D medicationsUF riskAnnual healthcare costsElectronic medical record algorithmCase-control studyLarge clinical populationFurther mechanistic researchBackgroundUterine fibroidsT2D diagnosisDiabetes exposureMedication typeDiabetes presenceInsulin usersUterine fibroidsInsulin treatmentProtective associationStratified analysisClinical cohortConclusionsThese dataProtective effectLarge cohortCase-control statusHealthcare costsT2DMedications
2016
Ketosis After Cardiopulmonary Bypass in Children Is Associated With an Inadequate Balance Between Oxygen Transport and Consumption*
Klee P, Arni D, Saudan S, Schwitzgebel VM, Sharma R, Karam O, Rimensberger PC. Ketosis After Cardiopulmonary Bypass in Children Is Associated With an Inadequate Balance Between Oxygen Transport and Consumption*. Pediatric Critical Care Medicine 2016, 17: 852-859. PMID: 27472253, DOI: 10.1097/pcc.0000000000000880.Peer-Reviewed Original ResearchConceptsIndependent risk factorPICU admissionCardiopulmonary bypassInsulin treatmentCardiac surgeryRisk factorsPostoperative blood glucose levelsProspective observational studyPatients 6 monthsSubset of patientsSubgroup of patientsVenous oxygen saturationTight glycemic controlBlood glucose levelsGlycemic controlTertiary PICUGlucose intakeWorse outcomesPatient outcomesHigh prevalenceObservational studyGlucose levelsOxygen saturationMetabolic constellationAdmission
2015
HbA1c overtesting and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study
McCoy RG, Van Houten HK, Ross JS, Montori VM, Shah ND. HbA1c overtesting and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study. The BMJ 2015, 351: h6138. PMID: 26646052, PMCID: PMC4673101, DOI: 10.1136/bmj.h6138.Peer-Reviewed Original ResearchConceptsType 2 diabetesGlycemic controlControlled type 2 diabetesNational administrative claims databaseExcessive testingAdministrative claims databaseGood glycemic controlStable glycemic controlStudy patientsTreatment intensificationSevere hypoglycemiaTreatment regimenStudy cohortUS patientsClaims databasePotential overtreatmentUS cohortHypoglycemic drugsInsulin treatmentPatient burdenRetrospective analysisStudy populationUS adultsDiabetes managementObservational populationC‐peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry
Gregg B, Connor CG, Cheng P, Ruedy KJ, Beck RW, Kollman C, Schatz D, Cengiz E, Tamborlane WV, Klingensmith GJ, Lee JM, Consortium F. C‐peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2015, 17: 274-280. PMID: 25940861, DOI: 10.1111/pedi.12280.Peer-Reviewed Original ResearchConceptsC-peptide levelsC-peptide measurementsLower body mass indexPediatric type 2 diabetesInsulin-treated patientsEndogenous insulin secretionPediatric diabetes centersC-peptide valuesBody mass indexType 2 diabetesT2D durationInsulin therapyClinical factorsDiabetes CenterClinic registryMass indexC-peptideInsulin secretionInsulin treatmentLarge cohortT2DMetabolic controlType 2Biologic dataRegistry
2014
Role of Synaptic Plasticity and EphA5-EphrinA5 Interaction Within the Ventromedial Hypothalamus in Response to Recurrent Hypoglycemia
Szepietowska B, Horvath TL, Sherwin RS. Role of Synaptic Plasticity and EphA5-EphrinA5 Interaction Within the Ventromedial Hypothalamus in Response to Recurrent Hypoglycemia. Diabetes 2014, 63: 1140-1147. PMID: 24222347, PMCID: PMC3931406, DOI: 10.2337/db13-1259.Peer-Reviewed Original ResearchConceptsRecurrent hypoglycemiaVentromedial hypothalamusEphA5 receptorNondiabetic ratsCounterregulatory responsesSynaptic plasticityAntecedent recurrent hypoglycemiaCounterregulatory hormone releaseDefective glucose counterregulationExpression of ephrinA5Counterregulatory hormone responsesIntensive insulin treatmentInsulin-induced hypoglycemiaHyperinsulinemic-hypoglycemic clamp studyGlucose infusion rateHypoglycemic clamp studiesGlucose counterregulationSynaptic coverageHypoglycemic stimulusGlucagon secretionGlucagon releaseAcute hypoglycemiaInsulin treatmentHormone releaseInfusion rateRole of Self-Efficacy in the Relationship Between Patient-Provider Relationships and Psychological Insulin Resistance Among Patients with Type 2 Diabetes.
Nam S, Nam S, Song Y. Role of Self-Efficacy in the Relationship Between Patient-Provider Relationships and Psychological Insulin Resistance Among Patients with Type 2 Diabetes. 2014, 1: 1-15. PMID: 25584361, PMCID: PMC4288822.Peer-Reviewed Original ResearchPsychological insulin resistancePatient-provider relationshipPatient-provider communicationEffective patient-provider communicationGood patient-provider relationshipOverall treatment adherenceType 2 diabetesSelf-care behaviorsInsulin resistanceDiabetes knowledgeInsulin treatmentPatients' self-care behaviorsOptimal glycemic controlCross-sectional studyQuality of lifeGlycemic controlPatient interviewsTreatment adherenceDiabetes AttitudesDiabetesPatientsPotential mechanismsIntervention programsTreatmentMediators
2013
Repeatable Noninvasive Measurement of Mouse Myocardial Glucose Uptake with 18F-FDG: Evaluation of Tracer Kinetics in a Type 1 Diabetes Model
Thorn SL, deKemp RA, Dumouchel T, Klein R, Renaud JM, Wells RG, Gollob MH, Beanlands RS, DaSilva JN. Repeatable Noninvasive Measurement of Mouse Myocardial Glucose Uptake with 18F-FDG: Evaluation of Tracer Kinetics in a Type 1 Diabetes Model. Journal Of Nuclear Medicine 2013, 54: 1637-1644. PMID: 23940301, DOI: 10.2967/jnumed.112.110114.Peer-Reviewed Original ResearchConceptsMyocardial glucose uptakeImage-derived blood input functionAcute insulin treatmentInsulin treatmentBlood activityType 1 diabetic miceType 1 diabetic mouse modelML/min/Glucose uptakeVena cava diameterMyocardial glucose uptake ratesDiabetic mouse modelType 1 diabetesStandardized uptake valueTest-retest repeatabilityAcute insulin stimulationDiabetic miceCoefficient of repeatabilityFDG-PETBland-Altman analysisMyocardial glucoseContrast CTBaseline scanMouse modelTime-activity curves
2012
Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual β-Cell Function
Sherr J, Tamborlane WV, Xing D, Tsalikian E, Mauras N, Buckingham B, White NH, Arbelaez AM, Beck RW, Kollman C, Ruedy K. Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual β-Cell Function. Diabetes Care 2012, 35: 817-820. PMID: 22323414, PMCID: PMC3308298, DOI: 10.2337/dc11-2190.Peer-Reviewed Original ResearchConceptsResidual β-cell functionΒ-cell functionSensor glucose levelsLower glucose variabilityType 1 diabetesGlucose levelsContinuous glucose monitoringT1D participantsGlucose variabilityMean sensor glucose levelPeak C-peptide levelsMixed meal tolerance testTarget A1C levelsC-peptide levelsLong-term T1DShort-term groupNondiabetic groupT1D groupA1c levelsT1D patientsLess hyperglycemiaNondiabetic individualsTolerance testInsulin treatmentHypoglycemia
2010
Relationship between Inpatient Hyperglycemia and Insulin Treatment after Kidney Transplantation and Future New Onset Diabetes Mellitus
Chakkera HA, Knowler WC, Devarapalli Y, Weil EJ, Heilman RL, Dueck A, Mulligan DC, Reddy KS, Moss AA, Mekeel KL, Mazur MJ, Hamawi K, Castro JC, Cook CB. Relationship between Inpatient Hyperglycemia and Insulin Treatment after Kidney Transplantation and Future New Onset Diabetes Mellitus. Clinical Journal Of The American Society Of Nephrology 2010, 5: 1669-1675. PMID: 20558559, PMCID: PMC2974410, DOI: 10.2215/cjn.09481209.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsInpatient hyperglycemiaKidney transplantationTransplant recipientsInsulin therapyNondiabetic kidney transplant recipientsDevelopment of NODATRisk of NODATNew-onset diabetesKidney transplant surgeryCapillary blood glucoseNondiabetic patientsYear posttransplantCardiovascular eventsNew onsetDiabetes mellitusMedical therapyAdjusted analysisStudy cohortRetrospective studyTransplant surgeryBlood glucoseSerum glucoseInsulin treatmentNODATFactors Associated With Psychological Insulin Resistance in Individuals With Type 2 Diabetes
Nam S, Chesla C, Stotts NA, Kroon L, Janson SL. Factors Associated With Psychological Insulin Resistance in Individuals With Type 2 Diabetes. Diabetes Care 2010, 33: 1747-1749. PMID: 20435797, PMCID: PMC2909055, DOI: 10.2337/dc10-0099.Peer-Reviewed Original ResearchConceptsType 2 diabetesMore psychological barriersPsychological insulin resistanceInterpersonal processesPsychosocial variablesInsulin resistancePsychological barriersInsulin treatmentPredictive relationshipDiabetes AttitudesFinal regression modelTight glucose controlPatient reluctanceGlucose controlPatient interviewsObservational studyCare communicationHealthcare providersDiabetesResearch designIndividualsEthnic minoritiesPatientsTreatmentInsulin
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply